Laboratory Corp. of America Holdings (NYSE:LH) Shares Bought by Securian Asset Management Inc

Securian Asset Management Inc raised its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 1.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 10,213 shares of the medical research company’s stock after acquiring an additional 111 shares during the period. Securian Asset Management Inc’s holdings in Laboratory Corp. of America were worth $1,766,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. ETF Managers Group LLC grew its stake in shares of Laboratory Corp. of America by 8.1% during the 1st quarter. ETF Managers Group LLC now owns 883 shares of the medical research company’s stock valued at $135,000 after buying an additional 66 shares during the period. Squar Milner Financial Services LLC grew its stake in shares of Laboratory Corp. of America by 6.4% during the 2nd quarter. Squar Milner Financial Services LLC now owns 1,090 shares of the medical research company’s stock valued at $188,000 after buying an additional 66 shares during the period. Hartford Investment Management Co. grew its stake in shares of Laboratory Corp. of America by 0.3% during the 2nd quarter. Hartford Investment Management Co. now owns 20,629 shares of the medical research company’s stock valued at $3,567,000 after buying an additional 67 shares during the period. Diversified Trust Co grew its stake in shares of Laboratory Corp. of America by 4.1% during the 2nd quarter. Diversified Trust Co now owns 1,763 shares of the medical research company’s stock valued at $305,000 after buying an additional 70 shares during the period. Finally, Private Trust Co. NA grew its stake in shares of Laboratory Corp. of America by 1.4% during the 2nd quarter. Private Trust Co. NA now owns 5,172 shares of the medical research company’s stock valued at $894,000 after buying an additional 72 shares during the period. Institutional investors own 89.72% of the company’s stock.

In related news, SVP Der Vaart Sandra D. Van sold 2,328 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $176.75, for a total transaction of $411,474.00. Following the completion of the sale, the senior vice president now directly owns 2,328 shares of the company’s stock, valued at approximately $411,474. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 3,100 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $170.00, for a total transaction of $527,000.00. Following the sale, the director now directly owns 22,233 shares of the company’s stock, valued at $3,779,610. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,491 shares of company stock valued at $3,677,189. 0.74% of the stock is owned by corporate insiders.

Shares of Laboratory Corp. of America stock opened at $165.86 on Friday. The company has a fifty day moving average price of $169.48 and a 200 day moving average price of $160.78. The company has a current ratio of 1.14, a quick ratio of 1.05 and a debt-to-equity ratio of 0.95. Laboratory Corp. of America Holdings has a twelve month low of $119.38 and a twelve month high of $178.44. The stock has a market cap of $16.47 billion, a price-to-earnings ratio of 15.05, a price-to-earnings-growth ratio of 1.54 and a beta of 1.05.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, July 25th. The medical research company reported $2.93 earnings per share for the quarter, topping analysts’ consensus estimates of $2.90 by $0.03. Laboratory Corp. of America had a net margin of 8.19% and a return on equity of 16.28%. The firm had revenue of $2.88 billion during the quarter, compared to analysts’ expectations of $2.89 billion. During the same period in the prior year, the company earned $2.98 EPS. The firm’s revenue was up .5% on a year-over-year basis. Analysts forecast that Laboratory Corp. of America Holdings will post 11.28 earnings per share for the current year.

Several brokerages have recently issued reports on LH. KeyCorp boosted their price objective on shares of Laboratory Corp. of America from $172.00 to $192.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Deutsche Bank raised shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating and boosted their price objective for the company from $180.00 to $220.00 in a research note on Thursday, June 20th. Barclays set a $200.00 price objective on shares of Laboratory Corp. of America and gave the company a “buy” rating in a research note on Monday, July 15th. Bank of America raised shares of Laboratory Corp. of America from an “underperform” rating to a “neutral” rating and set a $174.60 price objective for the company in a research note on Tuesday, July 16th. Finally, Canaccord Genuity boosted their price objective on shares of Laboratory Corp. of America from $155.00 to $165.00 and gave the company a “hold” rating in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the stock. Laboratory Corp. of America currently has an average rating of “Buy” and a consensus target price of $185.91.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

See Also: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.